The combined analysis of PD-L1 expression and tumor microenvironment might help to better stratify which patients will benefit from what type of immunotherapy and to prevent a priori exclusion of PD-L1 negative patients who might still benefit from checkpoint inhibitor therapy (21–23). The gene discussed is CD274; the disease is neoplasm.